Can we achieve affordable cancer medicine prices? Developing a pathway for change

Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):321-325. doi: 10.1080/14737167.2021.1898951. Epub 2021 Mar 12.

Author

Sabine Vogler¹

Affiliation

¹ WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG/Austrian National Public Health Institute), Vienna, Austria.

PMID: 33653228
DOI: 10.1080/14737167.2021.1898951

No abstract available

Keywords: Cancer medication; affordability; collaboration; evidence; medicines prices; sustainability; transparency.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / economics*
Costs and Cost Analysis
Drug Costs
Drugs, Essential / administration & dosage
Drugs, Essential / economics
Humans
Neoplasms / drug therapy*
Neoplasms / economics

Substances

Antineoplastic Agents
Drugs, Essential